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Background: Angiogenesis is the main therapeutic mechanism of cell therapy for cardiovascular diseases, but
diabetes is reported to reduce the function and number of progenitor cells. Therefore, we studied the effect of
streptozotocin-induced diabetes on the bone marrow-mesenchymal stem cell (MSC) function, and examined
whether diabetes-impaired MSC could be rescued by pretreatment with oxytocin.
Results: MSCs were isolated and cultured from diabetic (DM) or non-diabetic (non-DM) rat, and proliferation rate
was compared. DM-MSC was pretreated with oxytocin and compared with non-DM-MSC. Angiogenic capacity was
estimated by tube formation and Matrigel plug assay, and therapeutic efficacy was studied in rat myocardial
infarction (MI) model.
The proliferation and angiogenic activity of DM-MSC were severely impaired but significantly improved by
pretreatment with oxytocin. Krüppel-like factor 2 (KLF2), a critical angiogenic factor, was dramatically reduced in
DM-MSC and significantly restored by oxytocin. In the Matrigel plug assay, vessel formation of DM-BMSCs was
attenuated but was recovered by oxytocin. In rat MI model, DM-MSC injection did not ameliorate cardiac injury,
whereas oxytocin-pretreated DM-MSC improved cardiac function and reduced fibrosis.
Conclusions: Our results show that diabetes influenced MSC by reducing angiogenic capacity and therapeutic
potential. We demonstrate the striking effect of oxytocin on stem cell dysfunction and suggest the use of oxytocin
as a priming reagent in autologous stem cell therapy.
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Cell therapy with autologous bone marrow-mesenchymal
stem cells (MSC) is a promising and safe modality with
the potential for vascular regeneration in the treatment of
ischemic diseases. MSC can differentiate into vascular
lineage cells and can be directly incorporated into newly
formed vessels [1]. However, the initial clinical trials of
stem cell therapy after myocardial infarction failed to re-
produce the substantial benefits demonstrated in the pre-
clinical animal studies, especially in elderly patients [2-5].* Correspondence: cecilyk@chonnam.ac.kr
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reproduction in any medium, provided the orOne possible reason for the conflicting results in cell ther-
apy research is that the stem cells used in most of the ani-
mal studies were derived from young or healthy animals.
Diabetes, obesity, or aging influence stem cell numbers
and activities [6-11], thus the animal studies could not
predict the outcomes of autologous stem cell therapy for a
patient with diabetes or other risk factors [12,13].
Diabetes is widely recognized to be an independent risk
factor for coronary heart disease, stroke, peripheral arterial
disease, cardiomyopathy, and congestive heart failure
[14-17]. Furthermore, diabetes is closely associated with
poor neovascularization after ischemia [2]. Cells isolated
from diabetic patients are significantly impaired in their
ability to recover blood flow after ischemia compared with
cells isolated from healthy donors [3]. In addition, diabetic. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Animal characteristics after induction of diabetes
Non-diabetes Diabetes
Day 1 n = 10 n = 24
BW (g) 442.50 ± 20.43 461.47 ± 41.37
BG (mg/dL) 94.83 ± 8.70 92.47 ± 6.47
Day 28 n = 10 n = 17
BW (g) 558.33 ± 22.51 349.00 ± 67.96*
BG (mg/dL) 118.50 ± 9.27 571.58 ± 57.64*
HW (mg) 1.47 ± 0.01 1.16 ± 0.21*
TL (mm) 45.49 ± 0.78 44.60 ± 1.67
HW (g)/TL (mm) 32.28 ± 0.35 25.99 ± 4.17*
Data are presented as mean ± SD.
HW, heart weight; BW, body weight; BG, blood glucose; TL, tibia length.
*p < 0.01 vs non-diabetes.
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hind limb ischemia, partly as the result of a dysfunction of
endothelial progenitor cells [6]. There is no doubt that dia-
betes is not the only factor associated with dysfunction of
progenitor cells, but diabetes leads to significant cellular
dysfunction such as poor migration, reduced proliferation,
and poor vascular network formation [7]. Diabetes-related
changes in stem cells or progenitor cells may not only ac-
count for the reduced proliferation rate of these cells but
also for their limited angiogenic potential [18].
Oxytocin is a neurohypophyseal hormone expressed in
the hypothalamus. Previous studies revealed that oxytocin
induces cardiomyogenesis of embryonic stem cells [19]
and adult Sca-1 (+) stem cells [20], stimulates the migra-
tion of endothelial cells [21], and increases the engraftment
[22] and cardiac differentiation potency [23] of umbilical
cord blood-derived mesenchymal stem cells in infarcted
myocardium.
Krüppel-like factor 2 (KLF2), which was first cloned by
Lingrel and colleagues [24], is emerging as a master regu-
lator of endothelial quiescence, anti-inflammatory and an-
tithrombotic properties, and vascular tone by activating
atheroprotective and inhibiting atherogenic transcription
[25]. Proangiogenic cells isolated from aged mice showed
a lower level of KLF2 than do cells from young mice [26].
Despite growing evidence of cellular dysfunction, however,
the signaling pathways of stem cells in various physio-
logical and pathological niches remain to be investigated.
The potential disadvantage of autologous stem cells is
that patients with diabetes may have a decline in number
and regenerative capacity of bone marrow and circulat-
ing stem cells; thus, patients who have diabetes may
have not only damaged myocardium but also a lessened
capacity for repair.
In this study, we aim to compare bone marrow-MSCs
obtained from non-diabetic and diabetic rats, and examine
whether diabetes-insulted MSC could be rescued by pre-
treatment with oxytocin.
Results
Proliferation is reduced in DM-MSC and recovered
by oxytocin
Hyperglycemia was induced 4 weeks after streptozotocin
injection (Table 1), and the mortality was 29.17% in the
diabetic group. Fasting blood glucose was substantially in-
creased to 571.58 ± 57.64 g/dL. Isolated MSC were tested
for their capabilities to differentiate into adipocytes, chon-
drocytes and osteoblasts in vitro. The results showed that
MSC were capable of differentiating into adipocytes, chon-
drocytes and osteoblasts. The successful differentiations
into adipocytes, chondrocytes and osteoblasts were identi-
fied by positive staining with Oil Red O, Alcian Blue-PAS
and Alizarin Red S respectively (Figure 1A). Bone marrow-
MSCs were isolated from non-DM rats (non-DM-MSC)and DM rats (DM-MSC) to perform the experiments. The
proliferation rate of non-DM-MSC was lower to 79.43%
than that of DM-MSC at day 7 (Figure 1B) and recovered
by oxytocin treatment (Figure 1C).
Tube formation and KLF2 are reduced in DM-MSC and
recovered by oxytocin
Angiogenic capacity of MSC was assessed by in vitro angio-
genesis assay after treatment with PBS, oxytocin, curcumin,
carvedilol, or rosuvastatin. Our previous reports demon-
strated that oxytocin enhanced therapeutic activity of MSC
[23], and curcumin blocked inflammatory responses [27].
Carvedilol, a drug for the treatment of hypertension and
heart failure, inhibited endothelial inflammation. Rosuvasta-
tin is widely prescribed to control hypercholesterolemia,
and inhibited pro-inflammatory transcription factor nuclear
factor-κB (NF-κB) [28]. As shown in Figure 1A, Non-DM-
MSC was not affected by these reagents. DM-MSC treated
with PBS, curcumin (10 μM), carvedilol (10 μM), and rosu-
vastatin(10 μM) showed retarded tube formation. On the
other hand, tube formation was observed in oxytocin-
treated DM-MSC. Non-DM-MSC showed significant tube
formation on Matrigel within 3 hours, while few tubes were
formed in DM-MSC. Tube length and tube area were lower
in DM-MSC than in non-DM-MSC (0.10-fold and 0.15-
fold of non-DM-MSC, respectively, Figure 2A). After
pretreatment with 100 nM of oxytocin for 24 hours,
tube length was higher by 2.64-fold and tube network
area was higher by 10.34-fold in OT-DM-MSC than in
PBS-treated DM-MSC (Figure 2B). To examine the rela-
tionship of KLF2 with the angiogenic capacity of MSC,
KLF2 expression was analyzed. KLF2 mRNA was in-
duced by oxytocin in dose-dependent manner in DM-
MSC (Figure 3A). Both KLF2 mRNA and protein were
reduced in DM-MSC and successfully induced by oxy-
tocin pretreatment (Figure 3B,C).
To confirm whether the KLF2 is a mediator of oxytocin
in DM-MSC, knockdown of KLF2 was induced by siRNA
Figure 1 Impaired proliferation of MSC from DM bone marrow was restored by oxytocin. (A) Differentiation of MSC isolated from bone
marrow was induced into adipogenic, chondrogenic, or osteogenic lineage. (B) The proliferation rate was significantly reduced in DM-MSC (n=5).
(C) DM-MSC pretreated with oxytocin for 24 hours restored proliferation activity (n=5). * P<0.01 vs. Non-DM-MSC.
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mRNA and tube formation in KLF2 siRNA-transfected
DM-MSC (Figure 3D). This result suggested that oxy-
tocin might act on angiogenic potential of DM-MSC
through KLF2 induction.
To examine whether KLF2 induction by oxytocin is
specific to MSC, KLF2 plasmid DNA was transfected to
293T cells. Oxytocin treatment did not show any signifi-
cant induction of KLF2 protein in 293T cells (Figure 3E).
Impaired angiogenic capacity of DM-MSC is restored by
oxytocin
Gross findings were that neovascularization was induced
in Matrigel plugs containing non-DM-MSC and OT-DM-
MSC in the murine host (Figure 4A). Functional vessel
formation was determined by measuring the red blood
cell-containing area of vascular structures. The vascular-
ized area was reduced to 0.68-fold that of plugs containing
non-DM-MSC; by contrast, the vascularized area was im-
proved 1.42-fold by oxytocin treatment compared with
PBS treatment (Figure 4B). The vascularized area of DM-MSC was restored to a level similar to that of non-DM-
MSC by oxytocin treatment (0.130 ± 0.01% in non-DM-
MSC vs. 0.126 ± 0.01% in OT-DM-MSC, p > 0.05). The
numbers of CD31-positive cells were significantly reduced
by 0.36-fold in the DM-MSC-injected group compared
with the non-DM-MSC group and were restored to 0.77-
fold that of the non-DM-MSC group by oxytocin treat-
ment (Figure 4C).
Introducing exogenous KLF2 DNA into DM-MSC contrib-
utes to restoration of angiogenic activity of DM-MSC
To understand whether the loss of angiogenic potential is
associated with down-regulated KLF2 in DM-MSC, KLF2
plasmid DNA was transfected into DM-MSC before the
angiogenesis assay. After DNA transfection, KLF2 mRNA
and KLF2 protein were significantly induced at 1 day and
2 days, respectively. In addition, the expression of flag, a
tagging protein of transfected KLF2, was also well shown
in KLF2-transfected MSC (Figure 5A). Non-DM-MSC
showed no changes in tube formation after DNA transfec-
tion. Tube length was increased 1.37-fold and tube area
Figure 2 Impaired tube formation of MSC from DM bone marrow was restored by oxytocin. (A) MSCs were pretreated with PBS, oxytocin,
curcumin, carvedilol, or rosuvastatin prior to tube formation assay. (B) Representative images from the in vitro angiogenesis assay showed the
retarded tube formation in DM-MSC. Both tube length and tube area were measured and expressed in graphs (n=5). (C) Representative images
of tube formation of DM-MSC after treatment with PBS or 100 nM of oxytocin for 24 hours were presented (n=4). * p < 0.01 vs. Non-DM-MSC.
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compared with that of DM-MSC transfected with the
empty vector gWIZ (Figure 5B). These data showed that
the upregulation of KLF2 by oxytocin in DM-MSC was
consistent with the enhanced blood perfusion and capillary
density in the ischemic limbs that received OT-DM-MSC.
Restored therapeutic effects in myocardial infarction (MI)
by OT-DM-MSC
The therapeutic effect of DM-MSC was examined in MI
model. MSCs were injected into infarcted myocardium
after 7 days after MI. Histology and cardiac function wereassessed 14 days later. Compared with that in the PBS-
injected heart, cardiac fibrosis was reduced to 67.65% in
non-DM-MSC injected (p<0.01), 96.25% in DM-MSC
injected (p>0.01), and 73.68% in DM-MSC injected
(p<0.01) hearts (Figure 6A). GFP-labeled MSCs (green)
stained with vWF (red) were frequent in non-DM-MSC
or DM-MSC injected hearts, whereas seldom observed
in DM-MSC injected heart (Figure 6B). To examine
the angiogenesis in myocardium after MI, vWF expres-
sion in the whole heart was imaged. More vWF expres-
sion was observed in non-MD-MSC or OT-DM-MSC
injected heart, whereas less was in DM-MSC injected
Figure 3 Reduced KLF2 level of MSC from DM bone marrow was restored by oxytocin. (A) KLF2 mRNA was assessed in DM-MSC treated
with various concentrations oxytocin (n=3). (B) KLF2 mRNA was analyzed in MSC from non-DM or DM bone marrow treated with PBS or oxytocin
for 24 hours (n=3). (C) The level of KLF2 protein was reduced in DM-MSC, whereas restored by oxytocin (n=3). (D) Oxytocin-induced KLF2 mRNA
was assessed in DM-MSC transfected with scrambled siRNA or KLF2 siRNA (n=3). (E) After transfection with KLF2 plasmid for 24 hours, 293T cells
were treated with PBS or oxytocin for 24 hours. KLF2 protein level was examined by Western blot (n=3). Quantification analysis was performed
and data in the graph represented the mean ± standard deviation.
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growth factor (VEGF), hepatocyte growth factor (HGF),
and interleukin-10 (IL-10) were also examined (Figure 6D).
They were induced in Non-DM-MS-injected myocardium,
whereas hardly expressed in DM-MSC-injected myocar-
dium. In OT-DM-MSC-injected heart, VEGF, HGF, and
IL-10 were significantly induced compared with in DM-
MSC-injected heart. To verify the cardiac function, frac-
tional shortening (FS) and ejection fraction (EF) were
assessed. At 2 weeks, FS and EF were remained unchanged
in DM-MSC injected group compared with PBS injected
group. On the other hand, cardiac function was recovered
in non-DM-MSC injected group and DM-MSC injected
groups (Figure 6D).
Discussion
MSC are one of the most actively studied stem cell
sources for treating various cardiovascular diseases. Au-
tologous MSC application is clinically available without
ethical issues or immunological problems. The use of
autologous MSC, however, is affected by factors such as
aging or systemic diseases, which may contribute to the
functional impairment of stem cells. Diabetes is one of
the risk factors for cardiovascular diseases, and type 1
diabetes is a disorder characterized by hyperglycemia
and a proinflammatory state [29,30]. Our results showedthat diabetes impairs the neovascularization of bone
marrow-derived MSC, and these findings are consistent
with previous reports [31,32]. Several reports demonstrated
diabetes exerted a detrimental effect on stem cells or pro-
genitor cells. Endothelial progenitor cells obtained from
type 1 diabetes patients [31] or streptozotocin-induced dia-
betes mice [33] showed the significant reduction of circulat-
ing cell number and cellular function. Prolonged exposure
to high glucose condition has drastic effects on the differen-
tiation potential, proliferation capacity, and cell survival of
adipose tissue-derived MSC [9]. To overcome, we searched
for a priming reagent to restore the angiogenesis activity of
DM-MSC, and we found a transient treatment of DM-
MSC with oxytocin for 24 hours improved tube formation
capacity.
Oxytocin, a neurohypophyseal nonapeptide, modulates
social recognition, emotion, and the female reproductive
system [34]. In previous studies, we provided evidence for
beneficial roles of oxytocin in umbilical cord blood-derived
mesenchymal stem cells [22,23].
We next explored which effecter was controlled by oxy-
tocin to restore the angiogenic potential. A previous report
showed that cell number is reduced and KLF2 expression is
repressed in proangiogenic cells as a result of senescence
[26]. KLF2 is a well-known zinc-finger transcriptional regu-
lator that is involved in endothelial development, functional
Figure 4 Oxytocin significantly recovered neovascularization in the Matrigel plug assay (n=3). (A) Gross images of Matrigel plugs
harvested 2 weeks after subcutaneous injection into athymic nude mice. Note the substantial increased neovascularization in Matrigel containing
DM-MSC compared with PBS-containing Matrigel. (B) Representative H&E-stained images of Matrigel plugs; arrows indicate vascular structures
containing red blood cells. (C) The neovasculature formed by MSC in Matrigel plugs was quantified by immunohistochemical staining with
anti-human CD31 IgG. *p< 0.05 vs. Non-DM-MSC; # p< 0.05 vs. OT-DM-MSC.
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KLF2 inhibited function and expression of hypoxia-
inducible factor α (HIF1-α) in hypoxia-mediated endothelia
angiogenesis [37]. This discrepancy might be resulted from
different inducers of angiogenesis. KLF2 might be required
for development of physiological or therapeutic angiogen-
esis, and regulation of inflammation or hypoxia-induced
angiogenesis. In this study, we focused on intrinsic angio-
genic potential of MSC rather than on pathological lesion.
We found that KLF2 was highly expressed in normal MSC,
whereas it was significantly repressed in DM-MSC. Our
data and those of a previous report [26] show that down-
regulated KLF2 is closely associated with aggravation of the
angiogenic potential of stem/progenitor cells. In addition to
angiogenesis, oxytocin-treated DM-MSC successfully in-
duced as well anti-inflammatory IL-10 as angiogenic cyto-
kines such as VEGF and HGF in injected infarct lesion.The most important limitation in this study is that we
did not address the exact mechanism of KLF2 induction
by oxytocin.
Taken together, these results show that DM-MSC
showed impaired angiogenesis and reduced KLF2, which
were restored by oxytocin treatment. Stem cell therapy
with autologous MSC in persons with risk factors such as
diabetes, aging, or systemic disorders is expected to be less
effective than stem cell therapy in the preclinical animal
experiments. For therapeutic application, therefore, the fu-
ture challenge is to establish a safe procedure for patients
with risk factors to normalize the function of endogenous
stem cells before autologous stem cell application. We
suggest that strong potential exists for translating the re-
sults of the present study to human trials, which would be
very beneficial to patients who are at risk of cardiovascular
disease in the setting of diabetes.
Figure 5 Enforced expression of KLF2 into DM-MSC recovered
angiogenic activity (n=3). (A) Transfected KLF2 was measured by
RT-PCR and Western blot against KLF2 and flag. (B) After transfection
to non-DM-MSC or DM-MSC, tube formation was assessed and ana-
lyzed. *p < 0.05 vs mock-transfected DM-MSC.
Kim et al. BMC Cell Biology 2013, 14:38 Page 7 of 11
http://www.biomedcentral.com/1471-2121/14/38Conclusions
In the present study, we evaluated a putative relation be-
tween diabetes and poor angiogenesis of stem cells in
the myocardial infarction model. Our data showed that
the cellular function of MSC might be disturbed by ex-
posure to the diabetic niche. In addition, we studied oxy-
tocin and KLF2 in relation to the restoration of the
angiogenic potential of DM-MSC.
Methods
Experimental hyperglycemia
This study was approved by the Chonnam National Uni-
versity Institutional Animal Care and Use Committee
(CNU AICUC-H-2010-11). Twelve-week-old adult male
Sprague–Dawley rats (Jung Ang, Korea) received intraper-
itoneal injections of streptozotocin (65 mg/kg, Sigma,
USA) dissolved in 50 mM sodium citrate buffer (pH 4.5)to induce type 1 diabetes. Age-matched controls were
injected with an equivalent volume of saline. Fasting blood
glucose levels were measured in tail veins, and rats with a
blood glucose level > 250 mg/dl were considered to be
diabetic and were included in the study.
Culture of MSC and 293T cells
MSCs were isolated and cultured as described in previous
reports [38-40]. MSCs were obtained from the tibia and
femur under sterile conditions by using a syringe to flush
the cavity out with warmed phosphate-buffered saline
(PBS), collected by centrifugation, and resuspended with
DMEM with 10% fetal bovine serum. Cells were plated into
culture dishes, and nonadherent cells were removed by
changing the medium after 72 hours. All cells used in this
study were from the third and fourth passages of MSC. To
identify stemness, adipogenic, chondrogenic, and osteo-
genic differentiations were performed in monolayer culture
of MSC by using Stem Cell Differentiation Kits (Life tech-
nologies, USA). Briefly, MSC were cultured in growth
medium or differentiation medium. After 7 days, cells were
fixed in formalin and stained with Oil Red O (Sigm-Al-
drich, USA), Safranin O (Sigm-Aldrich, USA) and Alizarin
Red S (Sigm-Aldrich, USA) staining to determine the adi-
pogenesis, chondrogenesis and osteogenesis, respectively.
Oxytocin (100 nM, Sigma-Aldrich, USA), curcumin
(Sigma-Aldrich, USA), carvedilol (kindly provided by
Chong Kun Dang Pharm., Korea), and rosuvastatin calcium
(kindly provided by AstraZeneca Korea) were added to the
growth medium for 24 hours for the experiments. 293T
cells were purchased from the ATCC (USA) and main-
tained in Dulbecco’s Modified Eagle’s Medium (Invitrogen,
USA) supplemented with 10% fetal bovine serum (Invitro-
gen, USA).
Proliferation assay of MSCs
Cells were plated on 48-well plate and the proliferation
rate was measured with WST-1 (Roche Applied Science,
USA). Briefly, WST-1 reagent was added at each time
points, and the absorbance was measured at 490nm after
incubation for 2 hours.
In vitro angiogenesis assay
Tube formation was assayed by using an in vitro angio-
genesis assay kit (Chemicon, USA). Cells (1 × 104) were
plated onto matrix gel-coated 96-well plates and were cul-
tured in DMEM without serum. Tube formation was
monitored and photographed by using an inverted micro-
scope (Olympus CRX41, Japan), and images were analyzed
by using Image-Pro software (Media Cybernetics, Inc.,
USA). Angiogenic activity was quantified by measuring
tube length and tube area. Total tube length in four fields
per well was averaged, and three wells were used to pro-





Figure 6 (See legend on next page.)
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Figure 6 Cardiac fibrosis, expressions of angiogenic factors, and cardiac function were ameliorated by injection of OT-DM-MSC in
infarcted myocardium. (A) Representative images showed fibrosis was significantly reduced in Non-DM-MSC and DM-MSC-injected heart. (B) Repre-
sentative images of GFP-labeled MSCs (green) injected in infarcted myocardium showed expression of von Willebrand factor (vWF, red). The merged
images showed vWF-expressing MSC (yellow arrows) and none-expressing MSC (white arrows). (C) Distribution and degree of vWF expression in the
whole heart. Less vWF and restored vWF were observed in DM-MSC injected heart and DM-MSC injected heart after MI, respectively. (D) Expressions of
vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and interleukin-10 (IL-10) in infarcted myocardium were examined. (E)
Echocardiographic evaluations were performed 2 weeks after cell injection. * p < 0.01 vs PBS; # p < 0.01 vs DM-MSC.
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To compare the mRNA expression level of KLF2, RT-PCR
was done as previously described [23]. Primers were de-
signed from Bioneer (Daejeon, Korea) and the sequences
were as follows: human KLF2 forward, caagacctacaccaa-
gagttcgca, reverse, tacatgtgccgtttcatgtgcagc; rat KLF2 for-
ward, ttgcagctacaccaactgcg, reverse, tgtcgcttcatgtgcagagc;
rat glyceraldehydes 3-phosphate dehydrogenase (GAPDH)
forward, ggccaaggtcatccatga, reverse, tcagtgagcccaggatg.
Band densities were estimated using the Scion image 4.02
software (Scion Corporation, USA).
Western blot analysis
Cells were lysed and analyzed as previously described [23]
with blotting with KLF2 antibody (Novus Biologicals, USA)
and flag antibody(Sigma-Aldrich, USA). β-actin (Sigma,
USA) was used as a loading control. Band densities were
estimated using the Scion Image 4.02 software (Scion Cor-
poration, USA).
Plasmid DNA or siRNA transfection
KLF2 plasmid DNA was purchased from OriGene Tech-
nologies (Rockville, USA). MSC were transfected with
KLF2 plasmid DNA or gWIZ mammalian expression vec-
tor (Genlantis, USA) by using Lipofectamine 2000 (Invitro-
gen, USA) according to the manufacturer’s instruction.
Overexpression of KLF2 was confirmed by RT-PCR and
Western blot at 1 day and 2 days after transfection, re-
spectively. To study the effect of oxytocin on KLF2 expres-
sion, KLF2 plasmid DNA was transfected to 293T cells for
1 day, and then cells were treated with oxytocin or PBS for
1 day. To knock down KLF2, KLF2 siRNA and scrambled
siRNA (Bioneer, Korea) were transfected to DM-MSC with
Lipofectamine 2000. After 2 days, siRNA transfected cells
were treated with oxytocin (100 nM) for 24 hours.Matrigel plug assay
PBS or 2 × 105 cells were mixed with phenol-red-free
Matrigel (Matrigel™ Basement Membrane Matrix High
Concentration, BD Biosciences, USA), and subcutaneously
injected into 7-week-old male Balb/c athymic nude mice.
After 2 weeks, the Matrigel plugs were harvested and proc-
essed for analysis. To estimate the degree of vascularization,
H&E-stained digital images were analyzed by measuringthe erythrocyte-filled area and expressing that as a percent-
age of the total area of Matrigel.
Rat model of myocardial infarction (MI)
Male Sprague–Dawley rats (weighing 200–230 g, Jung
Ang Animals, Korea) were used to induced MI previously
described [23]. After 7 days, rats were randomly divided
into 4 groups (n=5 each group) and anesthetized for reop-
eration. To visualize the injected MSCs for immunohisto-
chemical examination, cells were infected with lenti-GFP
virus for 48 hours and washed out with PBS before injec-
tion. DM-MSCs were pretreated with PBS or oxytocin
(100 nM) for 24 hours before injection. Rats were injected
with PBS alone, non-DM-MSC, DM-MSC, or oxytocin-
pretreated DM-MSCs (OT-DM-MSC) into the peri-
infarct area. MSCs (5 × 105 diluted in 100 μL of PBS) were
directly injected into the peri-infarct area. Finally, the
heart was repositioned in the chest, and the chest was
closed. The animals remained in a supervised setting until
they were fully conscious.
Echocardiography
After 2 weeks, echocardiography was performed as pre-
viously described [23].
Immunohistochemical staining
For immunohistochemical analysis, slides were stained as
previously described [23] with primary antibodies against
von Willebrand factor (vWF, Biomedicals, Switzerland,
1:100), GFP (Abcam, USA), VEGF (Santa Cruz, USA),
HGF (Santa Cruz, USA), and IL-10 (Abcam, USA).
Statistical analysis
All data are presented as means ± SDs. P values were
calculated by using the unpaired Student’s t-test. For
analysis of the in vivo ischemia experiments, the Schef-
fe's test was performed for multiple comparisons after
ANOVA between the groups. A P < 0.05 was considered
statistically significant.
Abbreviations
MSC: Mesenchymal stem cell; BM: Bone marrow; DM: Diabetes mellitus;
MI: Myocardial infarction; KLF2K: Rüppel-like factor 2.
Competing interests
The authors declare that they have no competing interests.
Kim et al. BMC Cell Biology 2013, 14:38 Page 10 of 11
http://www.biomedcentral.com/1471-2121/14/38Authors’ contributions
YSK designed this study, performed experiments in cell culture, Mtrigel plug
assay, myocardial infarction surgery, transfection, and drafted manuscript. JSK
performed myocardial infarction surgery and cared experimental rats. MHH
performed cell isolation, RT-PCR, Western blot, and tube formation assay. WSK
performed plasmid manipulation and induction of diabetes in rats. HJ and HK
performed histologic studies. MHJ contributed to the conception of this study.
YA contributed the conception and design of this study. All authors read and
approved the manuscript.Acknowledgments
This study was supported by a grant of the National Research Foundation of
Korea Grant funded by the Korean Government (MEST), Republic of Korea
(2010–0020261), and the Korean Health Technology R&D Project, Ministry of
Health & Welfare, Republic of Korea (HI12C0199).
Author details
1Heart Research Center, Chonnam National University Hospital, 42
Jebong-Ro, Dong-Gu, Gwangju 501-757, South Korea. 2Research Laboratory
of Cardiovascular Regeneration, Chonnam National University Hospital, 42
Jebong-Ro, Dong-Gu, Gwangju 501-757, South Korea. 3Department of
Cardiology, Chonnam National University Hospital, 42 Jebong-RoDong-Gu,
Gwangju 501-757, South Korea.
Received: 16 May 2013 Accepted: 29 August 2013
Published: 11 September 2013References
1. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K,
Ishida H, Shimizu T, Kangawa K, et al: Monolayered mesenchymal stem
cells repair scarred myocardium after myocardial infarction. Nat Med
2006, 12(4):459–465.
2. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner
JM: Rescue of diabetes-related impairment of angiogenesis by intramus-
cular gene therapy with adeno-VEGF. Am J Pathol 1999, 154(2):355–363.
3. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C,
Spyridopoulos I, Chun J, Brinkmann V, Keul P, et al: Sphingosine-1-
phosphate stimulates the functional capacity of progenitor cells by
activation of the CXCR4-dependent signaling pathway via the S1P3
receptor. Arterioscler Thromb Vasc Biol 2007, 27(2):275–282.
4. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin
H, Zeiher AM, Dimmeler S: Profoundly reduced neovascularization
capacity of bone marrow mononuclear cells derived from patients with
chronic ischemic heart disease. Circulation 2004, 109(13):1615–1622.
5. Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A: Age-
dependent depression in circulating endothelial progenitor cells in
patients undergoing coronary artery bypass grafting. J Am Coll Cardiol
2003, 42(12):2073–2080.
6. Fadini GP, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, Agostini C,
Avogaro A: Diabetes impairs progenitor cell mobilisation after hindlimb
ischaemia-reperfusion injury in rats. Diabetologia 2006, 49(12):3075–3084.
7. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel
T: Circulating endothelial progenitor cells, vascular function, and
cardiovascular risk. N Engl J Med 2003, 348(7):593–600.
8. Alt EU, Senst C, Murthy SN, Slakey DP, Dupin CL, Chaffin AE, Kadowitz PJ,
Izadpanah R: Aging alters tissue resident mesenchymal stem cell
properties. Stem Cell Res 2012, 8(2):215–225.
9. Cramer C, Freisinger E, Jones RK, Slakey DP, Dupin CL, Newsome ER, Alt EU,
Izadpanah R: Persistent high glucose concentrations alter the
regenerative potential of mesenchymal stem cells. Stem Cells Dev 2010,
19(12):1875–1884.
10. Dentelli P, Barale C, Togliatto G, Trombetta A, Olgasi C, Gili M, Riganti C,
Toppino M, Brizzi MF: A diabetic milieu promotes OCT4 and NANOG
production in human visceral-derived adipose stem cells.
Diabetologia 2013, 56(1):173–184.
11. Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A,
Castellani C, Thiene G, Agostini C, Cappellari R, et al: Stem cell
compartmentalization in diabetes and high cardiovascular risk reveals
the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol
2013, 108(1):313.12. Li TS, Furutani A, Takahashi M, Ohshima M, Qin SL, Kobayashi T, Ito H,
Hamano K: Impaired potency of bone marrow mononuclear cells for
inducing therapeutic angiogenesis in obese diabetic rats. Am J Physiol
Heart Circ Physiol 2006, 290(4):H1362–H1369.
13. Zhang H, Fazel S, Tian H, Mickle DA, Weisel RD, Fujii T, Li RK: Increasing
donor age adversely impacts beneficial effects of bone marrow but not
smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol
2005, 289(5):H2089–H2096.
14. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W,
Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement
for healthcare professionals from the American Heart Association.
Circulation 1999, 100(10):1134–1146.
15. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon
MR, Dai S, de Simone G, Ford ES, et al: Heart disease and stroke statistics–
2011 update: a report from the American Heart Association. Circulation
2011, 123(4):e18–e209.
16. Orchard TJ, Costacou T, Kretowski A, Nesto RW: Type 1 diabetes and
coronary artery disease. Diabetes Care 2006, 29(11):2528–2538.
17. Cull CA, Jensen CC, Retnakaran R, Holman RR: Impact of the metabolic
syndrome on macrovascular and microvascular outcomes in type 2
diabetes mellitus: United Kingdom Prospective Diabetes Study 78.
Circulation 2007, 116(19):2119–2126.
18. Jin P, Zhang X, Wu Y, Li L, Yin Q, Zheng L, Zhang H, Sun C: Streptozotocin-
induced diabetic rat-derived bone marrow mesenchymal stem cells have
impaired abilities in proliferation, paracrine, antiapoptosis, and myogenic
differentiation. Transplant Proc 2010, 42(7):2745–2752.
19. Danalache BA, Paquin J, Donghao W, Grygorczyk R, Moore JC, Mummery
CL, Gutkowska J, Jankowski M: Nitric oxide signaling in oxytocin-mediated
cardiomyogenesis. Stem Cells 2007, 25(3):679–688.
20. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, Sano M, Toko H,
Akazawa H, Sato T, et al: Adult cardiac Sca-1-positive cells differentiate
into beating cardiomyocytes. J Biol Chem 2004, 279(12):11384–11391.
21. Cattaneo MG, Chini B, Vicentini LM: Oxytocin stimulates migration and
invasion in human endothelial cells. Br J Pharmacol 2008, 153(4):728–736.
22. Kim YS, Kwon JS, Hong MH, Kim J, Song CH, Jeong MH, Cho JG, Park JC,
Kang JC, Ahn Y: Promigratory activity of oxytocin on umbilical cord
blood-derived mesenchymal stem cells. Artif Organs 2010, 34(6):453–461.
23. Kim YS, Ahn Y, Kwon JS, Cho YK, Jeong MH, Cho JG, Park JC, Kang JC: Priming
of mesenchymal stem cells with oxytocin enhances the cardiac repair in
ischemia/reperfusion injury. Cells, tissues, organs 2012, 195(5):428–442.
24. Dekker RJ, van Thienen JV, Rohlena J, de Jager SC, Elderkamp YW, Seppen J,
de Vries CJ, Biessen EA, van Berkel TJ, Pannekoek H, et al: Endothelial KLF2
links local arterial shear stress levels to the expression of vascular tone-
regulating genes. Am J Pathol 2005, 167(2):609–618.
25. Anderson KP, Kern CB, Crable SC, Lingrel JB: Isolation of a gene encoding a
functional zinc finger protein homologous to erythroid Kruppel-like factor:
identification of a new multigene family. Mol Cell Biol 1995, 15(11):5957–5965.
26. Boon RA, Urbich C, Fischer A, Fontijn RD, Seeger FH, Koyanagi M,
Horrevoets AJ, Dimmeler S: Kruppel-like factor 2 improves
neovascularization capacity of aged proangiogenic cells. Eur Heart J 2011,
32(3):371–377.
27. Kim YS, Ahn Y, Hong MH, Joo SY, Kim KH, Sohn IS, Park HW, Hong YJ, Kim JH,
Kim W, et al: Curcumin attenuates inflammatory responses of TNF-alpha-
stimulated human endothelial cells. J Cardiovasc Pharmacol 2007, 50(1):41–49.
28. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, Kim JH, Kim W, Jeong
MH, Cho JG, et al: Rosuvastatin suppresses the inflammatory responses
through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB
in endothelial cells. J Cardiovasc Pharmacol 2007, 49(6):376–383.
29. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I: In-
creased monocytic activity and biomarkers of inflammation in patients
with type 1 diabetes. Diabetes 2006, 55(3):774–779.
30. Devaraj S, Dasu MR, Jialal I: Diabetes is a proinflammatory state: a
translational perspective. Expert Rev Endocrinol Metab 2010, 5(1):19–28.
31. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer
HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ: Endothelial
progenitor cell dysfunction: a novel concept in the pathogenesis of
vascular complications of type 1 diabetes. Diabetes 2004, 53(1):195–199.
32. Dernbach E, Randriamboavonjy V, Fleming I, Zeiher AM, Dimmeler S, Urbich
C: Impaired interaction of platelets with endothelial progenitor cells in
patients with cardiovascular risk factors. Basic Res Cardiol 2008,
103(6):572–581.
Kim et al. BMC Cell Biology 2013, 14:38 Page 11 of 11
http://www.biomedcentral.com/1471-2121/14/3833. Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT,
Doevendans PA, Verhaar MC: Impaired endothelial progenitor cell
mobilization and dysfunctional bone marrow stroma in diabetes
mellitus. PloS one 2013, 8(3):e60357.
34. Jankowski M, Hajjar F, Kawas SA, Mukaddam-Daher S, Hoffman G, McCann
SM, Gutkowska J: Rat heart: a site of oxytocin production and action.
Proc Natl Acad Sci USA 1998, 95(24):14558–14563.
35. Kuo CT, Veselits ML, Barton KP, Lu MM, Clendenin C, Leiden JM: The LKLF
transcription factor is required for normal tunica media formation and
blood vessel stabilization during murine embryogenesis. Genes Dev 1997,
11(22):2996–3006.
36. Wu J, Bohanan CS, Neumann JC, Lingrel JB: KLF2 transcription factor
modulates blood vessel maturation through smooth muscle cell
migration. J Biol Chem 2008, 283(7):3942–3950.
37. Kawanami D, Mahabeleshwar GH, Lin Z, Atkins GB, Hamik A, Haldar SM,
Maemura K, Lamanna JC, Jain MK: Kruppel-like factor 2 inhibits hypoxia-
inducible factor 1alpha expression and function in the endothelium.
J Biol Chem 2009, 284(31):20522–20530.
38. Lennon DP, Caplan AI: Isolation of rat marrow-derived mesenchymal stem
cells. Experimental hematology 2006, 34(11):1606–1607.
39. Karaoz E, Genc ZS, Demircan PC, Aksoy A, Duruksu G: Protection of rat
pancreatic islet function and viability by coculture with rat bone
marrow-derived mesenchymal stem cells. Cell death & disease 2010, 1:e36.
40. Costa AR, Panda NC, Yong S, Mayorga ME, Pawlowski GP, Fan K, Penn MS,
Laurita KR: Optical mapping of cryoinjured rat myocardium grafted with
mesenchymal stem cells. Am J Physiol Heart Circ Physiol 2012,
302(1):H270–H277.
doi:10.1186/1471-2121-14-38
Cite this article as: Kim et al.: Restoration of angiogenic capacity of
diabetes-insulted mesenchymal stem cells by oxytocin. BMC Cell Biology
2013 14:38.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
